Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03302234




Registration number
NCT03302234
Ethics application status
Date submitted
26/09/2017
Date registered
5/10/2017
Date last updated
26/09/2023

Titles & IDs
Public title
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
Scientific title
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS = 50%) (KEYNOTE-598)
Secondary ID [1] 0 0
MK-3475-598
Secondary ID [2] 0 0
3475-598
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Non-Small-Cell Lung 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Pembrolizumab
Other interventions - Ipilimumab
Other interventions - Placebo

Experimental: Pembrolizumab + Ipilimumab - Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus 1 mg/kg of ipilimumab by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.

Active Comparator: Pembrolizumab + Placebo - Participants receive 200 mg of pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus placebo by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.


Other interventions: Pembrolizumab
Administered as an intravenous (IV) infusion every 3 weeks (Q3W)

Other interventions: Ipilimumab
Administered as an IV infusion every 6 weeks (Q6W)

Other interventions: Placebo
Normal saline solution administered as an IV infusion Q6W
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to approximately 32 months (through data cut-off date: 01 Sep 2020)
Primary outcome [2] 0 0
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR)
Timepoint [2] 0 0
Up to approximately 32 months (through data cut-off date 01 Sep 2020)
Secondary outcome [1] 0 0
Objective Response Rate (ORR) Per RECIST 1.1 Based on BICR
Timepoint [1] 0 0
Up to approximately 32 months (data cut-off date 01 Sep 2020)
Secondary outcome [2] 0 0
Duration of Response (DOR) Per RECIST 1.1 Based on BICR
Timepoint [2] 0 0
Up to approximately 32 months (data cut-off date 01 Sep 2020)
Secondary outcome [3] 0 0
Time to True Deterioration (TTD) in Cough, Pain in Chest, and Shortness of Breath
Timepoint [3] 0 0
Up to approximately 32 months (data cut-off date 01 Sep 2020)
Secondary outcome [4] 0 0
Number of Participants Who Experienced an Adverse Event (AE)
Timepoint [4] 0 0
Up to approximately 27 months
Secondary outcome [5] 0 0
Number of Participants Who Discontinued Study Treatment Due to an AE
Timepoint [5] 0 0
Up to approximately 24 months
Secondary outcome [6] 0 0
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Scale Score to Week 18
Timepoint [6] 0 0
Baseline, Week 18

Eligibility
Key inclusion criteria
- Has a histologically or cytologically confirmed diagnosis of Stage IV metastatic
non-small cell lung cancer (NSCLC) (American Joint Committee on Cancer version 8)

- Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1
(RECIST 1.1) as determined by investigator

- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Has a life expectancy of at least 3 months

- Has provided archival tumor tissue sample or newly obtained core or excisional biopsy
of a tumor lesion not previously irradiated

- Female participants of childbearing potential must have a negative serum pregnancy
test within 72 hours prior to receiving the first dose of study therapy

- Female participants of reproductive potential must agree to use contraception starting
from the first dose of study medication, throughout the study period, and for up to
120 days after the last dose of study medication
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Has received prior systemic chemotherapy/other targeted or biological antineoplastic
therapy treatment for their Stage IV metastatic NSCLC

- Has a tumor that harbors an epidermal growth factor receptor (EGFR)-sensitizing
(activating) mutation or an anaplastic lymphoma kinase (ALK) translocation

- Is currently participating in or has participated in a trial of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study therapy

- Has received prior therapy with an anti-Programmed Cell Death Receptor 1 (PD-1),
anti-Programmed Cell Death Receptor Ligand 1 (anti-PD-L1), or anti- Programmed Cell
Death Receptor Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory
or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4
[CTLA-4], OX-40, CD137)

- Has received prior radiotherapy within 2 weeks of start of study therapy or received
lung radiation therapy of >30 Gray (Gy) within 6 months of the first dose of study
therapy

- Has recovered from all radiation-related toxicities, does not require corticosteroids,
and has not had radiation pneumonitis

- Is receiving systemic steroid therapy =7 days prior to the first dose of study therapy
or receiving any other form of immunosuppressive medication

- Has a known additional malignancy that is progressing or has required active treatment
within the past 3 years with the exception of curatively treated basal cell carcinoma
of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ
cancers

- Has known untreated central nervous system (CNS) metastases and/or carcinomatous
meningitis

- Has an active autoimmune disease that has required systemic treatment in past 2 years
(i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive
drugs)

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(i.e., doses exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior the first dose of study therapy

- Has a history of (non-infectious) pneumonitis that required systemic steroids or
current pneumonitis/interstitial lung disease

- Has had an allogeneic tissue/solid organ transplant

- Has received a live vaccine within 30 days prior to the first dose of study therapy

- Has an active infection requiring systemic therapy

- Has a known history of human immunodeficiency virus (HIV) infection

- Has a known history of hepatitis B or known active hepatitis C virus infection

- Has a known history of active tuberculosis

- Has known psychiatric or substance abuse disorders that would interfere with
cooperating with the requirements of the trial

- Is a regular user of any illicit drugs or had a recent history of substance abuse

- Is pregnant or breast feeding or expecting to conceive starting from the first dose of
study medication, throughout the study period, and for up to 120 days after the last
dose of study medication

- Has severe hypersensitivity to pembrolizumab and/or any of its excipients and/or to
ipilimumab and/or any of its excipients

- Has a c-ros oncogene 1 (ROS1) mutation

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/12/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
7/09/2022
Sample size
Target
Accrual to date
Final
568
Recruitment in Australia
Recruitment state(s)
QLD,WA
Recruitment hospital [1] 0 0
Mater Cancer Care Centre ( Site 2102) - South Brisbane
Recruitment hospital [2] 0 0
Fiona Stanley Hospital ( Site 2105) - Perth
Recruitment hospital [3] 0 0
Chris OBrien Lifehouse ( Site 2100) - Camperdown
Recruitment hospital [4] 0 0
The Townsville Hospital ( Site 2103) - Douglas
Recruitment hospital [5] 0 0
St Vincents Hospital Melbourne ( Site 2101) - Fitzroy
Recruitment postcode(s) [1] 0 0
4101 - South Brisbane
Recruitment postcode(s) [2] 0 0
6150 - Perth
Recruitment postcode(s) [3] 0 0
2050 - Camperdown
Recruitment postcode(s) [4] 0 0
4814 - Douglas
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Maine
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
New Jersey
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Oregon
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
United States of America
State/province [15] 0 0
Wisconsin
Country [16] 0 0
Argentina
State/province [16] 0 0
Rio Negro
Country [17] 0 0
Argentina
State/province [17] 0 0
Santa Fe
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Cordoba
Country [20] 0 0
Argentina
State/province [20] 0 0
La Rioja
Country [21] 0 0
Argentina
State/province [21] 0 0
Rosario
Country [22] 0 0
Argentina
State/province [22] 0 0
Tucuman
Country [23] 0 0
Brazil
State/province [23] 0 0
Pernambuco
Country [24] 0 0
Brazil
State/province [24] 0 0
Rio Grande Do Sul
Country [25] 0 0
Brazil
State/province [25] 0 0
RS
Country [26] 0 0
Brazil
State/province [26] 0 0
SP
Country [27] 0 0
Brazil
State/province [27] 0 0
Barretos
Country [28] 0 0
Brazil
State/province [28] 0 0
Florianopolis
Country [29] 0 0
Brazil
State/province [29] 0 0
Sao Paulo
Country [30] 0 0
Canada
State/province [30] 0 0
Alberta
Country [31] 0 0
Canada
State/province [31] 0 0
Manitoba
Country [32] 0 0
Canada
State/province [32] 0 0
Quebec
Country [33] 0 0
Chile
State/province [33] 0 0
El Maule
Country [34] 0 0
Chile
State/province [34] 0 0
Santiago
Country [35] 0 0
Chile
State/province [35] 0 0
Vina del Mar
Country [36] 0 0
Colombia
State/province [36] 0 0
Antioquia
Country [37] 0 0
Colombia
State/province [37] 0 0
Bogota
Country [38] 0 0
Colombia
State/province [38] 0 0
Monteria
Country [39] 0 0
Colombia
State/province [39] 0 0
Pasto
Country [40] 0 0
France
State/province [40] 0 0
Cedex 20
Country [41] 0 0
France
State/province [41] 0 0
Bordeaux
Country [42] 0 0
France
State/province [42] 0 0
Brest
Country [43] 0 0
France
State/province [43] 0 0
Creteil
Country [44] 0 0
France
State/province [44] 0 0
Le Mans
Country [45] 0 0
France
State/province [45] 0 0
Lille
Country [46] 0 0
France
State/province [46] 0 0
Paris
Country [47] 0 0
France
State/province [47] 0 0
Strasbourg
Country [48] 0 0
France
State/province [48] 0 0
Toulouse
Country [49] 0 0
Germany
State/province [49] 0 0
Berlin
Country [50] 0 0
Germany
State/province [50] 0 0
Gera
Country [51] 0 0
Germany
State/province [51] 0 0
Grosshansdorf
Country [52] 0 0
Germany
State/province [52] 0 0
Heidelberg
Country [53] 0 0
Germany
State/province [53] 0 0
Leipzig
Country [54] 0 0
Germany
State/province [54] 0 0
Luebeck
Country [55] 0 0
Hungary
State/province [55] 0 0
Budapest
Country [56] 0 0
Hungary
State/province [56] 0 0
Debrecen
Country [57] 0 0
Hungary
State/province [57] 0 0
Farkasgyepu
Country [58] 0 0
Hungary
State/province [58] 0 0
Gyor
Country [59] 0 0
Hungary
State/province [59] 0 0
Gyula
Country [60] 0 0
Hungary
State/province [60] 0 0
Szekesfehervar
Country [61] 0 0
Hungary
State/province [61] 0 0
Szolnok
Country [62] 0 0
Ireland
State/province [62] 0 0
Dublin
Country [63] 0 0
Ireland
State/province [63] 0 0
Limerick
Country [64] 0 0
Italy
State/province [64] 0 0
Foggia
Country [65] 0 0
Italy
State/province [65] 0 0
Milano
Country [66] 0 0
Italy
State/province [66] 0 0
Verona
Country [67] 0 0
Italy
State/province [67] 0 0
Brescia
Country [68] 0 0
Italy
State/province [68] 0 0
Monza
Country [69] 0 0
Italy
State/province [69] 0 0
Napoli
Country [70] 0 0
Italy
State/province [70] 0 0
Perugia
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Seoul
Country [72] 0 0
Latvia
State/province [72] 0 0
Riga
Country [73] 0 0
Mexico
State/province [73] 0 0
Jalisco
Country [74] 0 0
Mexico
State/province [74] 0 0
N.l.
Country [75] 0 0
Mexico
State/province [75] 0 0
Yucatan
Country [76] 0 0
Mexico
State/province [76] 0 0
Ciudad de Mexico
Country [77] 0 0
Mexico
State/province [77] 0 0
Mexico City
Country [78] 0 0
Mexico
State/province [78] 0 0
Puebla
Country [79] 0 0
Peru
State/province [79] 0 0
Lima
Country [80] 0 0
Peru
State/province [80] 0 0
Arequipa
Country [81] 0 0
Peru
State/province [81] 0 0
Trujillo
Country [82] 0 0
Poland
State/province [82] 0 0
Dolnoslaskie
Country [83] 0 0
Poland
State/province [83] 0 0
Zachodniopomorskie
Country [84] 0 0
Poland
State/province [84] 0 0
Brzeziny
Country [85] 0 0
Poland
State/province [85] 0 0
Bydgoszcz
Country [86] 0 0
Poland
State/province [86] 0 0
Konin
Country [87] 0 0
Poland
State/province [87] 0 0
Olsztyn
Country [88] 0 0
Poland
State/province [88] 0 0
Poznan
Country [89] 0 0
Poland
State/province [89] 0 0
Warszawa
Country [90] 0 0
South Africa
State/province [90] 0 0
Free State
Country [91] 0 0
South Africa
State/province [91] 0 0
Gauteng
Country [92] 0 0
South Africa
State/province [92] 0 0
Cape Town
Country [93] 0 0
South Africa
State/province [93] 0 0
Durban
Country [94] 0 0
South Africa
State/province [94] 0 0
Johannesburg
Country [95] 0 0
South Africa
State/province [95] 0 0
Kraaifontein
Country [96] 0 0
Spain
State/province [96] 0 0
Barcelona
Country [97] 0 0
Spain
State/province [97] 0 0
Extremadura
Country [98] 0 0
Spain
State/province [98] 0 0
Gran Canaria
Country [99] 0 0
Spain
State/province [99] 0 0
Madrid
Country [100] 0 0
Spain
State/province [100] 0 0
Sevilla
Country [101] 0 0
Taiwan
State/province [101] 0 0
Changhua
Country [102] 0 0
Taiwan
State/province [102] 0 0
Kaohsiung
Country [103] 0 0
Taiwan
State/province [103] 0 0
Taichung
Country [104] 0 0
Taiwan
State/province [104] 0 0
Tainan
Country [105] 0 0
Taiwan
State/province [105] 0 0
Taipei
Country [106] 0 0
Taiwan
State/province [106] 0 0
Taoyuan
Country [107] 0 0
Thailand
State/province [107] 0 0
Bangkok
Country [108] 0 0
Thailand
State/province [108] 0 0
Chiang Mai
Country [109] 0 0
Thailand
State/province [109] 0 0
Khon Kaen
Country [110] 0 0
Turkey
State/province [110] 0 0
Adana
Country [111] 0 0
Turkey
State/province [111] 0 0
Ankara
Country [112] 0 0
Turkey
State/province [112] 0 0
Bursa
Country [113] 0 0
Turkey
State/province [113] 0 0
Cankaya - Ankara
Country [114] 0 0
Turkey
State/province [114] 0 0
Edirne
Country [115] 0 0
Turkey
State/province [115] 0 0
Istanbul
Country [116] 0 0
Turkey
State/province [116] 0 0
Izmir
Country [117] 0 0
Turkey
State/province [117] 0 0
Kocaeli
Country [118] 0 0
Turkey
State/province [118] 0 0
Malatya
Country [119] 0 0
Turkey
State/province [119] 0 0
Trabzon
Country [120] 0 0
Ukraine
State/province [120] 0 0
Dnipropetrovsk Region
Country [121] 0 0
Ukraine
State/province [121] 0 0
Cherkasy
Country [122] 0 0
Ukraine
State/province [122] 0 0
Chernivtsy
Country [123] 0 0
Ukraine
State/province [123] 0 0
Dnipropetrovsk
Country [124] 0 0
Ukraine
State/province [124] 0 0
Ivano-Frankivsk
Country [125] 0 0
Ukraine
State/province [125] 0 0
Kropyvnytskyi
Country [126] 0 0
Ukraine
State/province [126] 0 0
Kyiv
Country [127] 0 0
Ukraine
State/province [127] 0 0
Lviv
Country [128] 0 0
Ukraine
State/province [128] 0 0
Odesa
Country [129] 0 0
United Kingdom
State/province [129] 0 0
Cornwall
Country [130] 0 0
United Kingdom
State/province [130] 0 0
Surrey
Country [131] 0 0
United Kingdom
State/province [131] 0 0
Belfast
Country [132] 0 0
United Kingdom
State/province [132] 0 0
London
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Manchester
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Northwood
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the efficacy of pembrolizumab given in combination
with either ipilimumab or placebo as first-line treatment in participants with metastatic
non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall
survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive
pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.

With Amendment 6 (effective date: 11-Dec-2020), active participants, investigator, and
sponsor personnel or delegate(s) involved in the treatment administration or clinical
evaluation of the participants will be unblinded. Participants will discontinue ipilimumab
and placebo and participants who remain on treatment will receive open-label pembrolizumab
only.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03302234
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03302234